TY - JOUR
T1 - Pediatric oncology
AU - Kurmasheva, Raushan T.
AU - Houghton, Peter J.
N1 - Funding Information:
We are grateful to Cynthia Nelson, Department of Chemical Biology and Therapeutics, for providing Figure 1 . This work was supported partly by Public Health Service awards from the National Cancer Institute (CA23099, CA7776, CA21685 Cancer Center Support Grant) and by American, Lebanese, Syrian Associated Charities (ALSAC).
PY - 2007/8
Y1 - 2007/8
N2 - Intensive use of cytotoxic agents in multimodality therapeutic regimens has resulted in almost 80% five-year disease-free survival and cure in the majority of childhood cancer patients. However, such success has come at the expense of severe acute or delayed toxicities and an increased occurrence of secondary cancers. With an increasing understanding of the genetic changes that underlie transformation in childhood cancer, rational approaches using agents that target these transforming events are being developed. Current and future strategies in developing tumor-selective therapy using inhibitors of signaling pathways dysregulated in leukemias (FLT3, NOTCH1) and solid/brain tumors (ErbB1-4, IGF-IR, PTCH1), and the challenges in developing less toxic, but equally effective treatments in pediatric oncology are presented.
AB - Intensive use of cytotoxic agents in multimodality therapeutic regimens has resulted in almost 80% five-year disease-free survival and cure in the majority of childhood cancer patients. However, such success has come at the expense of severe acute or delayed toxicities and an increased occurrence of secondary cancers. With an increasing understanding of the genetic changes that underlie transformation in childhood cancer, rational approaches using agents that target these transforming events are being developed. Current and future strategies in developing tumor-selective therapy using inhibitors of signaling pathways dysregulated in leukemias (FLT3, NOTCH1) and solid/brain tumors (ErbB1-4, IGF-IR, PTCH1), and the challenges in developing less toxic, but equally effective treatments in pediatric oncology are presented.
UR - http://www.scopus.com/inward/record.url?scp=34548119857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548119857&partnerID=8YFLogxK
U2 - 10.1016/j.cbpa.2007.05.037
DO - 10.1016/j.cbpa.2007.05.037
M3 - Review article
C2 - 17652007
AN - SCOPUS:34548119857
SN - 1367-5931
VL - 11
SP - 424
EP - 432
JO - Current Opinion in Chemical Biology
JF - Current Opinion in Chemical Biology
IS - 4
ER -